|Day Low/High||165.42 / 167.29|
|52 Wk Low/High||114.27 / 197.00|
DUBLIN, Aug. 2, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it will release second quarter 2019 financial results on Tuesday, August 6, 2019, prior to the open of U.
Retail investors are sitting pretty after Trump enacted more tariffs. See their fancy footwork executed in July.
The Fed chairman's news conference threw markets for a loop with hawkish words that did not support the Fed's dovish actions.
Actress encourages women to take active roles in their reproductive health, including researching birth control options
Edward Jones' Investment Strategist says Q3 and Q4 earnings season will be solid but not spectacular. Here's why.
-- Global Action Follows Notification of Updated Safety Information from the U.S.
U.S. stock futures are lower as U.S.-China trade talks are set to resume; the Department of Justice launches a new probe into whether Alphabet, Amazon, Facebook and Apple have been stifling competition; Tesla, Boeing, Ford, Facebook and Caterpillar report earnings.
- Dividend to be Paid on September 13, 2019 -
First Biosimilar Avastin® and Herceptin® Products to Launch in the United States
A federal judge yesterday greenlighted a class-action lawsuit against Allergan subsidiaries Warner Chilcott and Watson for overcharging direct purchasers for Loestrin 24, Minastrin and generic equivalents, according to Hagens Berman.
-- Filing included data from the Phase 3 ARTEMIS studies, which demonstrated that the majority of patients remained treatment free for at least 1 year following 3 treatments with Bimatoprost Sustained-Release --
Here are my five rules for handling earnings season.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AGN, BPFH, TRTN Downgrades: HMG, PIH Initiations: DHXM Read on to get TheStreet Quant Ratings' detailed report:
Jim Cramer says save the bubble-talk for the bathtub. The money investors can make in the market is real, and due to ingenuity, competitiveness and economic growth.
Jim Cramer weighs in on Planet Fitness, Allergan, Amarin, MPLX, Zynerba Pharmaceuticals, Schnieder National, United Parcel Service and more.
-- Allergan MIND™, Allergan's migraine franchise, showcases data highlighting BOTOX® (onabotulinumtoxinA) for Chronic Migraine, and two investigational products: ubrogepant and atogepant --
Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.
There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.
Watch the Russell 2000, housing activity, and mergers and acquisitions.
AbbVie's deal for Allergan will give it a new revenue stream in Botox, helping offset potential lower revenue from arthritis drug Humira, which is losing patent protection.
The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.
The ActionAlertsPLUS team breaks down what investors need to know on Tueday, including: AbbVie's acquistion of Allergan, Warren Buffett's Kraft comments and Micron earnings after the bell.
After days of complacency, we see a shift in sentiment and folks are getting the jitters.
NEW YORK, June 25, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Allergan Plc ("Allergan" or the "Company") (NYSE: AGN) in connection with the proposed...
AbbVie takes over Allergan. But, it's not the biggest deal of 2019...
Major indexes declined Tuesday after Federal Reserve Chairman Jerome Powell hedged on a possible rate cut.
Despite the financial positivity, many analysts warn the deal could have hiccups ahead.
The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.
AbbVie to purchase botox maker Allergan in $63 billion deal, but is the price just right?
Allergan shares surged the most in more than 25 years Tuesday after the Botox maker agreed to a $63 billion takeover from biopharmaceutical group AbbVie .
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.